Literature DB >> 23396092

Diagnostic value of contrast-enhanced ultrasonography in the characterization of ovarian tumors().

L M Sconfienza1, N Perrone, A Delnevo, F Lacelli, C Murolo, N Gandolfo, G Serafini.   

Abstract

INTRODUCTION: Vascularity influences the characteristics of gynecologic tumors observed with direct imaging techniques that reveal the macrovascular component of these lesions (color and power Doppler) and with indirect imaging involving the administration of contrast agents to examine the microcirculation and interstitial perfusion (contrast-enhanced computed tomography [CT] and magnetic resonance [MR] imaging). The purpose of this study was to determine whether contrast-enhanced ultrasonography (CEUS) of ovarian lesions provides useful information that cannot be obtained with conventional US.
MATERIALS AND METHODS: We used CEUS to assess 72 nonspecific adnexal lesions in 61 patients. CEUS was performed with a 4.8-ml bolus of a second-generation ultrasonographic contrast agent and dedicated imaging algorithms. For each lesion, B-mode morphology, CEUS morphology, and time/intensity curves were evaluated.
RESULTS: In 8/61 cases (13.1%) CEUS offered no additional morphovascular information. In 38/61 cases (62.3%), it provided additional information that did not modify the management of the lesion, and in 15/61 cases (24.6%) it gave additional information that modified the management of the lesion. Malignant lesions were characterized by significantly shorter times to peak enhancement (11.9 ± 3.1 s vs 19.8 ± 4.0 s p < 0.01) and significantly higher peak intensity (24.7 ± 4.2 dB vs 17.8 ± 3.3 dB p < 0.01) compared with benign lesions.
CONCLUSIONS: CEUS improves diagnostic confidence in the characterization of liquid-corpuscular lesions where conventional US is inconclusive. CEUS can be proposed as a valid alternative to CT and MR. However, information obtained by CEUS influences the therapy in a limited percentage of cases (24.6%).

Entities:  

Keywords:  Adnexal masses; Contrast-enhanced ultrasound; Ovarian cancer

Year:  2009        PMID: 23396092      PMCID: PMC3552646          DOI: 10.1016/j.jus.2009.09.007

Source DB:  PubMed          Journal:  J Ultrasound        ISSN: 1876-7931


  24 in total

1.  US characterization of ovarian masses: a meta-analysis.

Authors:  K Kinkel; H Hricak; Y Lu; K Tsuda; R A Filly
Journal:  Radiology       Date:  2000-12       Impact factor: 11.105

Review 2.  Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) Group.

Authors:  D Timmerman; L Valentin; T H Bourne; W P Collins; H Verrelst; I Vergote
Journal:  Ultrasound Obstet Gynecol       Date:  2000-10       Impact factor: 7.299

3.  Estimating the world cancer burden: Globocan 2000.

Authors:  D M Parkin; F Bray; J Ferlay; P Pisani
Journal:  Int J Cancer       Date:  2001-10-15       Impact factor: 7.396

4.  Prospective cross-validation of Doppler ultrasound examination and gray-scale ultrasound imaging for discrimination of benign and malignant pelvic masses.

Authors:  L Valentin
Journal:  Ultrasound Obstet Gynecol       Date:  1999-10       Impact factor: 7.299

5.  [Evaluation of using Levovist in the differential diagnosis of ovarian tumors].

Authors:  M Szymański; W Szymański; M Grabiec; J Korenkiewicz
Journal:  Ginekol Pol       Date:  1999-06       Impact factor: 1.232

6.  Contrast-enhanced sonography in the examination of benign and malignant adnexal masses.

Authors:  M R Ordén; S Gudmundsson; P Kirkinen
Journal:  J Ultrasound Med       Date:  2000-11       Impact factor: 2.153

7.  Contrast-enhanced, three-dimensional power Doppler sonography for differentiation of adnexal masses.

Authors:  S Kupesic; A Kurjak
Journal:  Obstet Gynecol       Date:  2000-09       Impact factor: 7.661

8.  Color Doppler energy prediction of malignancy in adnexal masses using logistic regression models.

Authors:  H Marret; R Ecochard; B Giraudeau; F Golfier; D Raudrant; J Lansac
Journal:  Ultrasound Obstet Gynecol       Date:  2002-12       Impact factor: 7.299

9.  Kinetics of a US contrast agent in benign and malignant adnexal tumors.

Authors:  Maija-Riitta Ordén; Jukka S Jurvelin; Pertti P Kirkinen
Journal:  Radiology       Date:  2003-02       Impact factor: 11.105

Review 10.  [Sonographic diagnosis of ovarian tumors: pre-operative Doppler evaluation].

Authors:  H Marret; F Tranquart; S Sauget; J Lansac
Journal:  J Radiol       Date:  2003-11
View more
  6 in total

1.  The Multimodal Ultrasound Features of Ovarian Serous Surface Papillary Borderline Tumor.

Authors:  Lijun Xie; Xinxiu Liu; Haiying Li; Liyan Huang; Fang Chen; Xingfu Wang; Lei Jiang; Ling Gan
Journal:  Womens Health Rep (New Rochelle)       Date:  2022-05-10

2.  A preliminary study: The sequential use of the risk malignancy index and contrast-enhanced ultrasonography in differential diagnosis of adnexal masses.

Authors:  Li Qiu; Fan Yang; Hong Luo
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

3.  Value of Transvaginal Two-Dimensional Contrast-Enhanced Ultrasonography in Diagnosing Atypical Ovarian Corpus Luteum Hematoma.

Authors:  Hui Liu; Hong Xiang; Ruixue Mu; Palida Tuoerhan; Qianqian Zeng; Huili Zhou; Rong Hu; Gulinaer Shahai
Journal:  Biomed Res Int       Date:  2018-10-09       Impact factor: 3.411

4.  Contrast-enhanced ultrasound of ovarian steroid cell tumor, not otherwise specified: A case report.

Authors:  Mai Sun; Bo Zhang
Journal:  Oncol Lett       Date:  2022-09-05       Impact factor: 3.111

5.  The contribution of qualitative CEUS to the determination of malignancy in adnexal masses, indeterminate on conventional US - a multicenter study.

Authors:  Xinling Zhang; Yongjiang Mao; Rongqin Zheng; Zhijuan Zheng; Zeping Huang; Dongmei Huang; Jing Zhang; Qing Dai; Xiaodong Zhou; Yanling Wen
Journal:  PLoS One       Date:  2014-04-15       Impact factor: 3.240

6.  Application Value of Color Doppler Ultrasound and Ultrasound Contrast in the Differential Diagnosis of Ovarian tumor.

Authors:  Haijing Zhang; Jinming Wang; Rui Guo
Journal:  Pak J Med Sci       Date:  2020 Jan-Feb       Impact factor: 1.088

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.